JPMorgan has downgraded its recommendation on Ipsen to Overweight Neutral and reduced its target price of 100 to 80 euros. The risk / return balance is less attractive since the arrival of the generics of Somatuline and the doubts about the approval of palovaretene, writes the broker.
AOF 2022
|
|
| ||||
IPSEN technical analysis trends
| Short term | Middle term | Long term | |
| Trends | Decline | Decline | Bullish |
Evolution of the Profit and Loss Account
Sale  Purchase | |
| Average recommendation | KEEP |
| Number of Analysts | 17 |
| Last Closing Price | € 78.70 |
| Average course objective | € 92.68 |
| Deviation / Average Target | 17.8% |
Officers and Directors
| Var. Jan 1 | Capi. (M $) | ||
 | IPSEN | -2.24% | 7,309 |